Source: Fortune
Summary
The obesity rate in the U.S. declined from 39.9% in 2022 to 36.4% in 2026, partly due to GLP-1 weight-loss drugs like Wegovy and Zepbound. Usage of these medications has increased tenfold since 2022, with prices dropping from over $1,000 to as low as $149 per month. The development of GLP-1 drugs began in 1990 with a peptide from Gila lizard venom, patented by Dr. John Eng. Amylin Pharmaceuticals later developed the first GLP-1 drug for diabetes, approved in 2005. Patents enabled innovation, leading to more convenient dosing and additional therapeutic uses. As patents expire, generic versions will further lower costs and increase access.
Our Reading
The numbers tell one story.
GLP-1 drugs are seeing massive adoption and price drops.
Patents enabled the first breakthroughs and subsequent innovation.
Competition among drugmakers is driving down costs.
The patent system, not just the lizard, is the real hero here.
The patent system turns risky research into marketable products.
Author: Evan Null
How the Gila Monster Helped Revolutionize Medicine
In 1990, Dr. John Eng discovered a peptide in Gila monster venom that mimicked human GLP-1. This discovery laid the foundation for modern weight-loss and diabetes treatments. The peptide’s unique properties—remaining active in the body longer than natural GLP-1—made it a valuable target for drug development. By 2005, Amylin Pharmaceuticals had turned this discovery into a diabetes drug, approved by the FDA. The patent system allowed for this innovation, giving companies time to recoup their investments.
The Role of Patents in Drug Development
Patents are crucial for pharmaceutical innovation. They require inventors to disclose their discoveries publicly, in exchange for a limited period of exclusivity. This exclusivity allows companies to recover the high costs of drug development. Without patents, many groundbreaking treatments would never reach the market. The GLP-1 drugs are a prime example of how patents can lead to long-term benefits for patients and society.
Competition and Price Drops
As more GLP-1 drugs entered the market, competition increased, leading to lower prices. What once cost over $1,000 per month is now available for as little as $149. This trend is expected to continue as more patents expire and generic versions become available. The price reductions have made these treatments more accessible to a wider population, contributing to the decline in obesity rates.
Future Innovations and Expanding Uses
Researchers are exploring new applications for GLP-1 drugs beyond weight loss and diabetes. Studies suggest they may help with conditions like opioid addiction, Alzheimer’s, and even cancer. These potential uses highlight the versatility of the original discovery. As more companies invest in GLP-1 research, the medical community may see even more breakthroughs in the coming years.
The Economic Impact of GLP-1 Drugs
Obesity and diabetes cost the U.S. healthcare system billions annually. GLP-1 drugs have the potential to reduce these costs by preventing or managing these conditions. Their impact extends beyond individual health, offering economic benefits to the broader society. As more people gain access to these treatments, the long-term financial burden on the healthcare system could decrease significantly.
